We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Immune Disease Model Points to Treatment for COVID-19 Cytokine Storms

News   May 28, 2020 | Original story from Cincinnati Children’s

 
Immune Disease Model Points to Treatment for COVID-19 Cytokine Storms

This is a microscopic photo of a blood smear from a transgenic mouse that mimics the human immune disorder, secondary HLH (hemophagocytic lymphohistiocytosis). The image shows macrophage immune cells (indicated by arrow) flooding healthy tissue cells during a cytokine storm caused by HLH in a very similar fashion t what occurs in patients with severe COVID-19 disease. Researchers reporting in the Journal of Allergy and Clinical Immunology say the HLH data were a factor in a decision to test the anti-inflammatory drug ruxolitinib (used to treat secondary HLH) in patients with COVID-19 in China. Credit: Cincinnati Children's

 
 
Advertisement
 

RELATED ARTICLES

Repurposing Drugs To Manage COVID-19 Progression

News

Researchers have used a large-scale human genetics study to identify drug targets important for managing COVID-19 in its early stages.

READ MORE

Tacking Treatment-Resistant Fungus With New Formulation of Existing Drugs

News

Researchers have discovered a formulation of existing medicines that can significantly reduce the presence of the fungus Candida auris on skin, controlling its spread and potentially keeping it from forming infections that have a high mortality rate.

READ MORE

Targeted Opioid Treats Colitis Pain Without Causing Side Effects in Mice

News

An opioid that exclusively targets diseased tissues and spares healthy tissues has been shown to relieves pain from inflammatory bowel disease without causing side effects, in mouse studies.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE